Umoja Biopharma Closes an Oversubscribed $210 Million Series B

Aitechpark17 Jun, 2021Technology

Series B financing co-led by SoftBank Vision Fund 2 and Cormorant Asset Management Financing accelerates development of Umoja?s pipeline of in vivo engineered CAR T cell immunotherapies and internal manufacturing capabilities Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing. The proceeds will enable Umoja to continue development of its integrated technologies, advance its product candidates based on CAR T-cell adapter-mediated tumor-targeting (TumorTag) and the in vivo modification of immune cells (VivoVec and RACR/CAR) into clinical development, and build internal manufacturing capabilities to support preclinical and clinical development of its pipeline programs.